Compare two steroid taper schedules for giant cell arteritis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 3 study compares how two standard steroid dose-reduction (tapering) schedules work for people with giant cell arteritis. It aims to see which taper approach controls the disease while reducing problems from long-term steroid use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older.
- Your doctor has confirmed giant cell arteritis (“temporal arteritis”) using specific test results (like biopsy, artery scans, or ultrasound).
- You started taking steroid tablets within the last 14 days, at an initial dose of 1 mg per kg per day or less.
- You can give written consent to join the study.
- You can reliably attend visits at the study center (you live within 150 km).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests abatacept to treat giant cell arteritis (GCA), a blood vessel inflammation that can cause headaches and vision risk. It’s for people with newly diagnosed or returning (relapsing) GCA with active symptoms in the last 8 weeks.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study tests whether bosentan, a medicine usually used for blood pressure in the lungs, can help control inflammation and symptoms in patients with giant cell arteritis (GCA). The goal is to see if it can reduce the need for steroids and improve quality of life.
This trial is for people newly diagnosed with giant cell arteritis (GCA) who have a 'halo' sign on their temporal artery ultrasound. It will study how quickly the halo disappears after starting steroid treatment, helping doctors understand the best way to use steroids for this condition.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial tests if a shorter course of the steroid prednisone, combined with tocilizumab, works as well as a longer course for giant cell arteritis. You must already be starting tocilizumab and taking at least 20 mg of prednisone daily.
Hear when a new Giant Cell Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.